Effects of nintedanib on circulating biomarkers in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Shervin Assassi,¹ Masataka Kuwana,² Christopher P Denton,³ Toby M Maher,⁴ Claudia Diefenbach,⁵ Carina Ittrich,⁵ Martina Gahlemann,⁶ Oliver Distler⁷ on behalf of the SENSCIS trial investigators

¹Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, USA; ²Department of Allergy and Rheumatology, Nippon Medical School, Houston, TX, USA; ²Department of Allergy and Rheumatology, Nippon Medical School, Houston, UK; ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁵Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

- compared with placebo.¹
- pulmonary fibrosis.^{2,3}





Scan QR code or visit URL for a device-friendly version of this poster including a voiceover from the lead author.

Scan QR code or visit URL for a webpage featuring BI-supported publications at EULAR 2022.

INTERACTIVE

espiratory/EULAR2022/Assass

REFERENCES Distler O et al. N Engl J Med 2019;380:2518–2528. 2. Wollin L et al.] Scleroderma Relat Disord 2019;4:212–218. 3. Wollin L et al. Eur Respir J 2019;54:1900161.

ACKNOWLEDGEMENTS AND DISCLOSURES

The SENSCIS trial was supported by Boehringer Ingelheim International GmbH (BI). The authors did not receive payment for the development of this poster. Julie Fleming of FleishmanHillard, London, UK, provided writing, editorial and formatting assistance, which was contracted and funded by BI. BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. Christopher Denton reports grants from Arxx Therapeutics, CSL Behring, GlaxoSmithKline, Inventiva, Servier; consulting fees from AbbVie, Acceleron, Bayer, BI, Corbus, CSL Behring, GlaxoSmithKline, Horizon Therapeutics, Inventiva, Roche, Sanofi; and fees for presentations from BI, Kymera, Mitsubishi Tanabe; consultancy fees from AbbVie, Acceleron Pharma, Alcimed, Altavant Sciences, Amgen, AnaMar, Arxx Therapeutics, AstraZeneca, Bayer, Blade Therapeutics, BI, Corbus Pharmaceuticals, CSL Behring, 4P-Pharma, 4P Science, Galapagos, Glenmark Pharmaceuticals, CSL Behring, 4P-Pharma, 4P Science, Galapagos, Glenmark Pharmaceuticals, Inventiva, Kymera, Lupin, Merck Sharp & Dohme, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Pfizer, Prometheus Biosciences, Redx Pharma, Roivant Sciences, Sanofi, Topadur; speaking fees from Bayer, BI, Janssen, Medscape; and holds patent US8247389 for the Executive Committee for the Board of Trustees for the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) and the Hartmann Müller Foundation, and a Senate member of the Swiss Academy of Medical Sciences.